Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $196

Benzinga Newsdesk www.benzinga.com Positive 77.1%

Neg 0% Neu 0% Pos 77.1%

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $193 to $196.